Lenalidomide and Novel Immunomodulatory Drugs (IMiDs®): A New Approach to the Regulation of Erythropoiesis and Hemoglobin Synthesis in Anemia.
Laure Moutouh de Parseval(Bristol-Myers Squibb (Switzerland)), Kyle Chan, Dominique Verhelle(Pfizer (United States)), Christopher Morris(University of South Florida), Helen Brady, Laura G. Corral, Roger Chen(UNSW Sydney), Emilia Glezer
Cited by 3
Related Papers
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
|Cancer Research|2015|275
Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells
|Cancer Research|2007|232
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
|Journal of Clinical Investigation|2008|180